MA33609B1 - Molecules de liaison a dll4 - Google Patents

Molecules de liaison a dll4

Info

Publication number
MA33609B1
MA33609B1 MA34722A MA34722A MA33609B1 MA 33609 B1 MA33609 B1 MA 33609B1 MA 34722 A MA34722 A MA 34722A MA 34722 A MA34722 A MA 34722A MA 33609 B1 MA33609 B1 MA 33609B1
Authority
MA
Morocco
Prior art keywords
molecules
dll4
link
relates
binding molecules
Prior art date
Application number
MA34722A
Other languages
Arabic (ar)
English (en)
Inventor
Eric Borges
Andreas Gschwind
Joachim Boucneau
Tavernier Evelyn De
Joost Kolkman
Pascal Merchiers
Hoorick Diane Van
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42083895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33609(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA33609B1 publication Critical patent/MA33609B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)

Abstract

L'invention concerne des molécules de liaison à Dll4, de préférence des domaines variables uniques d'immunoglobuline de liaison à Dll4 tels que des VHH et VH, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement de maladies qui sont associées à des effets à médiation par Dll4 sur l'angiogenèse. L'invention concerne également des acides nucléiques codant pour des molécules de liaison à Dll4, des cellules hôtes et des procédés pour les préparer.
MA34722A 2009-10-02 2012-03-26 Molecules de liaison a dll4 MA33609B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172132 2009-10-02
PCT/EP2010/064693 WO2011039368A2 (fr) 2009-10-02 2010-10-01 Molécules de liaison à dll4

Publications (1)

Publication Number Publication Date
MA33609B1 true MA33609B1 (fr) 2012-09-01

Family

ID=42083895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34722A MA33609B1 (fr) 2009-10-02 2012-03-26 Molecules de liaison a dll4

Country Status (24)

Country Link
US (1) US20110195494A1 (fr)
EP (1) EP2483313A2 (fr)
JP (1) JP2013506410A (fr)
KR (1) KR20120115217A (fr)
CN (1) CN102648210A (fr)
AP (1) AP2012006167A0 (fr)
AR (1) AR078516A1 (fr)
AU (1) AU2010302587A1 (fr)
BR (1) BR112012007294A2 (fr)
CA (1) CA2775420A1 (fr)
CL (1) CL2012000818A1 (fr)
EA (1) EA201200549A1 (fr)
EC (1) ECSP12011828A (fr)
IL (1) IL218544A0 (fr)
IN (1) IN2012DN02715A (fr)
MA (1) MA33609B1 (fr)
MX (1) MX2012003797A (fr)
NZ (1) NZ598650A (fr)
PE (1) PE20121184A1 (fr)
PH (1) PH12012500524A1 (fr)
TN (1) TN2012000144A1 (fr)
TW (1) TW201124532A (fr)
UY (1) UY32917A (fr)
WO (1) WO2011039368A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
EP3297672B1 (fr) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Protéines trispécifiques de liaison et méthodes d'utilisation
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
JP7215997B2 (ja) 2016-11-23 2023-01-31 ハープーン セラピューティクス，インク． 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
WO2018160754A2 (fr) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Protéine monovalente inductible de fixation d' antigène
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
CA3078969A1 (fr) 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Proteines trispecifiques et methodes d'utilisation
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
CN109160948B (zh) * 2018-09-21 2021-07-16 成都阿帕克生物科技有限公司 一种乙肝表面抗原纳米抗体及核酸分子和应用
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
WO2020232303A1 (fr) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. Protéines de liaison à epcam et méthodes d'utilisation
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
CN116547006B (zh) * 2021-08-06 2024-09-20 贝达药业股份有限公司 抗pd-l1纳米抗体及其应用
AR130878A1 (es) * 2022-10-26 2025-01-29 Berking Biotechnology Spa ANTICUERPO DE DOMINIO ÚNICO - sdAb / Vhh CONTRA LA NUCLEOPROTEÍNA DEL VIRUS SARS-CoV-2
WO2025043019A1 (fr) * 2023-08-21 2025-02-27 The Research Foundation For The State University Of New York Anticorps à domaine unique de liaison à slc4a1 (bande 3) pour une rétention sanguine accrue
CN120058935B (zh) * 2023-11-30 2026-01-13 科弈(浙江)药业科技有限公司 靶向egfr的纳米抗体、药物偶联物及其用途
CN119861194B (zh) * 2025-03-25 2025-06-03 中国计量大学 一种检测牛乳酪蛋白的纳米酶免疫层析方法及试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1361892A4 (fr) 2001-01-17 2004-10-13 Trubion Pharmaceuticals Inc Proteines de fusion d'immunoglobuline de domaine de liaison
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
WO2003059934A2 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Proteines de fusion d'albumine
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558645B1 (fr) 2002-11-08 2011-07-27 Ablynx N.V. Anticorps a domaine unique stabilises dans une composition pharmaceutique pour inhalation
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
JP5087274B2 (ja) 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
US8048418B2 (en) * 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
PL1962895T3 (pl) * 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
JP2009539870A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
WO2008070513A1 (fr) * 2006-12-01 2008-06-12 Alcon Research, Ltd. Modulation de psa-ncam utilisée dans le traitement des yeux secs
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof

Also Published As

Publication number Publication date
WO2011039368A3 (fr) 2011-06-23
IN2012DN02715A (fr) 2015-09-11
PH12012500524A1 (en) 2012-11-26
IL218544A0 (en) 2012-05-31
WO2011039368A2 (fr) 2011-04-07
TN2012000144A1 (en) 2013-09-19
CA2775420A1 (fr) 2011-04-07
BR112012007294A2 (pt) 2016-11-22
CL2012000818A1 (es) 2012-10-19
CN102648210A (zh) 2012-08-22
AR078516A1 (es) 2011-11-16
ECSP12011828A (es) 2012-05-30
AU2010302587A1 (en) 2012-04-05
MX2012003797A (es) 2012-06-28
US20110195494A1 (en) 2011-08-11
KR20120115217A (ko) 2012-10-17
UY32917A (es) 2011-04-29
AP2012006167A0 (en) 2012-04-30
NZ598650A (en) 2014-03-28
EP2483313A2 (fr) 2012-08-08
PE20121184A1 (es) 2012-09-16
JP2013506410A (ja) 2013-02-28
EA201200549A1 (ru) 2012-12-28
TW201124532A (en) 2011-07-16

Similar Documents

Publication Publication Date Title
MA33607B1 (fr) Molécules de liaison bispécifiques pour une thérapie anti-angiogénique
MA34979B1 (fr) Molecules de liaisonbispecifiques se liant a vegf et ang2
MA35233B1 (fr) Molecules de liaison bispecifiques se liant à dii4 et ang2
EA201200549A1 (ru) Dll4-связывающие молекулы
Couturier et al. Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
MA56289B1 (fr) Mutéines d'interleukine-21 et méthodes de traitement
MA40972B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
MX2009002418A (es) Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
NO20083793L (no) Antistoffer mot amyloid-beta peptid
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
CA2820681C (fr) Utilisation de lymphocytes t modifies par un recepteur chimerique d'antigenes chimerique pour traiter le cancer
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
JOP20220357A1 (ar) ربط أجسام مضادة متعددة الخصوصية مع bcma
CO6551686A2 (es) Inmunoglobinas con dominio variable dual y usos de las mismas
PH12013500410B1 (en) Vegf-binding molecules
BR112013028655A8 (pt) Anticorpos anti-fator de crescimento neuronal, composição farmacêutica compreendendo os mesmos e kit para o tratamento de dor em felinos
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA39342B2 (fr) Anticorps il -21
WO2008118324A3 (fr) Composition et procédé de traitement du cancer avec un anticorps anti-uroplakine ib